# Study on the Level of Neuromuscular Blockade

> **NCT03782233** · NA · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 83 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
- **DRUG:** A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).

## Key facts

- **NCT ID:** NCT03782233
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782233, "Study on the Level of Neuromuscular Blockade". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03782233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*